Yingjie Ji

Yingjie Ji

Auto-generated profile, based on publicly available information

Yingjie Ji

Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
QCQi Chen
Qi Chen
XLXiaohua Long
Xiaohua Long
YJYingjie Ji
Yingjie Ji
XLXiao Liang
Xiao Liang
DLDongping Li
Dongping Li
HLHong Lu
Hong Lu

25 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YJYingjie Ji
Yingjie Ji
HLHong Lu
Hong Lu
The purpose of this study was to evaluate the efficacy of high dose of metronidazole in the treatment of Helicobacter pylori (H. pylori) infection. Studies were identified from databases (Pubmed, Embase, Cochrane Library, ClinicalTrials.gov) searched from January 1990 to September 2017 using a battery of keywords. We included randomized controlled trials (RCTs) of H. pylori treatment comparing the high-dose and low-dose metronidazole-containing therapies (high-dose and low-dose therapies). Two reviewers independently selected studies, extracted relevant data and assessed study quality. A meta-analysis was performed by using Review Manager 5.3. Dichotomous data were pooled to obtain the relative risk (RR) of the eradication rate, with 95% confidence intervals (CIs). Four randomized controlled trials, a total of 612 patients with a diagnosis of H. pylori infection were included. Overall the meta-analysis showed that both high-dose and low-dose therapies achieved similar efficacy of intention-to-treat (ITT) eradication rate 82% vs. 76%, RR 1.12 (95%CI: 0.96 to 1.30), P = 0.15, and adherence 94% vs. 94%, RR 1.00 (95%CI: 0.97 to 1.04), P = 0.81, but side effects were more likely in high-dose therapies [32% vs. 17%, RR 1.84 (95%CI: 1.17 to 2.88), P = 0.008]. In subgroup analysis, increasing the dose of metronidazole enhanced eradication rates in areas with high metronidazole resistance [74% vs 52%, RR 1.40 (95%CI: 1.08 to 1.82), P = 0.01] and in individuals with metronidazole-resistant strains [71% vs. 46%, RR 1.50 (95%CI: 1.02 to 2.19), P = 0.04]. Both high-dose and low-dose therapies can achieve similar eradication rates and adherence and generally low-dose therapies cause fewer side effects. In populations with high metronidazole resistance, high dose of metronidazole can increase the eradication rates of H. pylori infection.

19 May 2020 in Helicobacter
Verified
Journal Article
Open access
PDF file
LLLaisheng Luo
Laisheng Luo
YHYu Huang
Yu Huang
XLXiao Liang
Xiao Liang
YJYingjie Ji
Yingjie Ji
LYLou Yu
Lou Yu
HLHong Lu
Hong Lu
Background: Helicobacter pylori (H pylori) treatment remains a challenge for penicillin‐allergic patients.Aim: To evaluate the efficacy and tolerability of susceptibility‐guided first‐line and rescue treatment in H pylori‐infected penicillin‐allergic patients.Methods: Consecutive H pylori‐infected patients with penicillin allergy received a 14‐day triple or quadruple therapy based on susceptibility to clarithromycin, levofloxacin, and metronidazole. All received esomeprazole 20 mg twice a day. Metronidazole‐susceptible infections received metronidazole plus clarithromycin or levofloxacin triple therapy if susceptible. Clarithromycin‐ and levofloxacin‐resistant infections received metronidazole plus tetracycline triple therapy. Metronidazole‐resistant infections received a bismuth—high‐dose metronidazole plus clarithromycin or levofloxacin quadruple therapy. Triple‐resistant infections received classical bismuth quadruple therapy with high‐dose metronidazole. Antimicrobial susceptibility was assessed using the E test method.Results: 112 patients were entered (34.8% men, average 47.1 years). Infections in 83.8% (31/37) of treatment‐naive subjects and 12.0% (9/75) (P < .001) receiving rescue treatment were susceptible to at least one of the three tested antibiotics. Overall, susceptibility‐guided therapy achieved eradication rates of 92.9% (104/112, 95% CI 88.1%‐97.7%) by intent‐to‐treat analysis and 99% (100/101, 95% CI 97.1%‐100%) by per‐protocol analysis. All regimens achieved eradication rates greater than 90% (P = .327) in the PP populations. Adverse events were relatively frequent; however, compliance remained high.Conclusion: Susceptibility‐guided therapy proved highly effective for penicillin‐allergic patients. When available and proven locally effective, the alternative was empiric classical bismuth quadruple therapy. This trial is registered with ClinicalTrials.gov as NCT03708848.

4 February 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LLLaisheng Luo
Laisheng Luo
YJYingjie Ji
Yingjie Ji
LYLou Yu
Lou Yu
YHYu Huang
Yu Huang
XLXiao Liang
Xiao Liang
HLHong Lu
Hong Lu

25 December 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYingjie Ji
Yingjie Ji
XLXiao Liang
Xiao Liang
HLHong Lu
Hong Lu
Backgrounds: There have been reports of Helicobacter pylori (H. pylori) in the oral cavity and it has been suggested that the oral cavity may be a reservoir for H. pylori reflux from the stomach. Objectives: High-throughput pyrosequencing was used to assess the structure and composition of oral microbiota communities in individuals with or without confirmed H. pylori infection. Methods: Saliva samples were obtained from 34 H. pylori infected and 24 H. pylori uninfected subjects. Bacterial genomic DNA was extracted and examined by pyrosequencing by amplification of the 16S rDNA V3-V4 hypervariable regions followed by bioinformatics analysis. Saliva sampling was repeated from 22 of the 34 H. pylori infected subjects 2 months after H. pylori eradication. Results: High-quality sequences (2,812,659) clustered into 95,812 operational taxonomic units (OTUs; 97% identity), representing 440 independent species belonging to 138 genera, 68 families, 36 orders, 21 classes, and 11 phyla. Species richness (alpha diversity) of H. pylori infected subjects was similar to that of uninfected subjects. Eradication treatment decreased saliva bacterial diversity. Beta diversity analysis showed that the salivary microbial community structure differed between H. pylori infected and uninfected subjects both before and after H. pylori eradication. Conclusions: Salivary microbiota diversity was similar in H. pylori infected and uninfected individuals. Antibiotic therapy was associated with a decline in salivary bacterial diversity. Both H. pylori infection and its eradication caused the oral microbiota alterations in community and structure. The present of H. pylori in oral cavity was not related with its infection status in stomach.